Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Medical College of Wisconsin
University of Colorado, Denver
Seagen Inc.
Merck Sharp & Dohme LLC
University of Kentucky
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
University of Michigan Rogel Cancer Center
Eastern Cooperative Oncology Group
Dana-Farber Cancer Institute
R-Pharm
University of Texas Southwestern Medical Center
University of Leipzig
University of California, San Diego
Mayo Clinic
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Icahn School of Medicine at Mount Sinai
Heidelberg University
University of California, San Diego
University of Michigan Rogel Cancer Center
CHU de Reims
Xinqiao Hospital of Chongqing
Radiation Therapy Oncology Group
University of Pittsburgh
Centre Henri Becquerel
Centre Henri Becquerel
Jacobio Pharmaceuticals Co., Ltd.
Kura Oncology, Inc.
Seagen Inc.
University of Pittsburgh
Immutep S.A.S.
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC
Incyte Corporation
Alpha Tau Medical LTD.
UNICANCER
Wake Forest University Health Sciences
Washington University School of Medicine
Medical University of South Carolina
Dana-Farber Cancer Institute
Dragonfly Therapeutics
University of Southern California
BeiGene
PDS Biotechnology Corp.
Centre Antoine Lacassagne
Centre Antoine Lacassagne
Hoffmann-La Roche
BioAtla, Inc.